To include your compound in the COVID-19 Resource Center, submit it here.

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

High dose filgotinib meets ulcerative colitis endpoints
A 200 mg dose of filgotinib from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) met the primary endpoints in the placebo-controlled Phase IIb/III SELECTION trial to treat moderate-to-severe ulcerative colitis, including clinical remission at Week 10 and maintaining

Read the full 463 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE